Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Immunitybio Inc maintains a gross margin of 99.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -168.95%, while the net margin is -161.83%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively IBRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IBRX competes directly with industry leaders such as MDGL and PRAX. With a market capitalization of $10.05B, it holds a leading position in the sector. When comparing efficiency, IBRX's gross margin of 99.00% stands against MDGL's 92.39% and PRAX's N/A. Such benchmarking helps identify whether Immunitybio Inc is trading at a premium or discount relative to its financial performance.
